ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

ClinicalTrials.gov ID: NCT06268886

Public ClinicalTrials.gov record NCT06268886. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 12:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Global Proof-of-concept Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease (TargetTau-1)

Study identification

NCT ID
NCT06268886
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
310 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range
50 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 19, 2024
Primary completion
Mar 17, 2027
Completion
Mar 17, 2027
Last update posted
Jul 23, 2025

2024 – 2027

United States locations

U.S. sites
14
U.S. states
2
U.S. cities
12
Facility City State ZIP Site status
Local Institution - 0068 Chandler Arizona 85226-3732
Local Institution - 0102 Gilbert Arizona 85297-0441
Local Institution - 0019 Phoenix Arizona 85004
Local Institution - 0018 Scottsdale Arizona 85253
Local Institution - 0026 Scottsdale Arizona 85258-4595
Local Institution - 0077 Tucson Arizona 85718-6522
Local Institution - 0038 Tucson Arizona 85718-6632
Local Institution - 0164 Encino California 91316-1511
Local Institution - 0139 Fullerton California 92835-1040
Local Institution - 0191 Irvine California 92614-9403
Local Institution - 0234 Long Beach California 90804-2128
Local Institution - 0142 Los Alamitos California 90720-3589
Local Institution - 0037 Napa California 94558-2415
Local Institution - 0209 Sacramento California 95816

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06268886, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 23, 2025 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06268886 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →